Verona Pharma plc VRNA
Trading inactive
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Raghuram Selvaraju | H.C. Wainwright | 104.67 $ | 107 $ | 2.33 % | 14/07/2025 |
| Boobalan Pachaiyappan | Roth Capital | 45.2 $ | 68 $ | 22.80 % | 10/01/2025 |
| Tiago Fauth | Wells Fargo | 49.55 $ | 74 $ | 24.45 % | 08/01/2025 |
| Raghuram Selvaraju | H.C. Wainwright | 38.39 $ | 42 $ | 3.61 % | 05/11/2024 |
| Edward Nash | Canaccord Genuity | 22.95 $ | 37 $ | 14.05 % | 22/07/2024 |
| Raghuram Selvaraju | H.C. Wainwright | 14.69 $ | 36 $ | 21.31 % | 27/06/2024 |
| Andrew Tsai | Jefferies | 12.5 $ | 38 $ | 25.50 % | 28/05/2024 |
| Yasmeen Rahimi | Piper Sandler | 15.8 $ | 36 $ | 20.20 % | 16/04/2024 |
| Andreas Argyrides | Wedbush | 18.05 $ | 30 $ | 11.95 % | 20/12/2022 |
| Edward Nash Nash | Canaccord Genuity | 10.25 $ | 27 $ | 16.75 % | 30/08/2022 |
| Liana Moussatos Moussatos | Wedbush | 9.9 $ | 23 $ | 13.10 % | 30/08/2022 |
| Raghuram Selvaraju Selvaraju | H.C. Wainwright | 9.9 $ | 30 $ | 20.10 % | 30/08/2022 |